Top News
CSIR-CDRI’s COVID-19 drug candidate Umifenovir secures DCGI approval for phase III...
This drug has a good safety profile and acts by preventing the entry of virus into human cells and also by priming the immune system......................
Krishgen Biosystems releases two latest Assays for SARS-CoV-2
Mumbai-based biotech company, Krishgen Biosystems has released two latest Assays for SARS-CoV-2 (Covid-19) Research - GENLISA surrogate Virus Neutralization Test ELISA and the GENLISA Inhibitor Screening ELISA..............
A definitive genetic diagnosis is the first step towards precision medicine,...
At a recently held webinar, the experts discussed available genetic testing in pediatric endocrinology, their applications, utility, differences and limitations as a part of an initiative to continue the medical education process..................
Agriculture
Govt releases guidelines for evaluation of nano-based Agri-input & food products
These ‘Guidelines’ would help policy makers and regulators to frame effective provisions for future novel nano-based products in the agri-input and food sectors of India.....................
Education
JNCASR kicks off crash course in molecular diagnosis of infectious diseases...
The course is designed to impart theoretical knowledge as well as hands-on training. Only simulated samples, not containing an infectious virus, have been used for training..................
Face to Face
“Indian healthcare scenario will improve significantly”
Mentioned Dr Alok Roy, Chairman, Medica Group of Hospitals in an exclusive interaction with the BioVoice where he shared his views on the issues surrounding healthcare sector in India.................
Chat with BioVoice
“COVID-19 pandemic has created a new world reality”
In an exclusive interaction with the BioVoice, Dr Rishi Bhatnagar, President, Aeris Communications, and Chairperson of The Institution of Engineering and Technology - IoT panel talked about various aspects of dealing with pandemic including the role of technology and communication.....................
